Skip to content

Engineering Evaluation of the Helix Ventilator

Engineering Evaluation of the Helix Ventilator

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03613363
Enrollment
20
Registered
2018-08-03
Start date
2018-06-06
Completion date
2021-09-07
Last updated
2025-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric ALL, Pulmonary Disease, Respiratory Disease

Brief summary

This study will be used to evaluate and observe the overall performance and controls of the Helix ventilator. Pressure and flow data between participants' current devices and the Helix ventilator will be assessed in either invasive or non-invasive ventilation. To evaluate ventilator performance, pressure and waveform data will be assessed as well. Also, patient and caregiver feedback will be captured. The target population is infants to adults weighing more than 5kg. Participants will be recruited by Boston Children's Health Physician's Group. Up to thirty participants will be enrolled in the study.

Detailed description

Following the completion of the informed consent, participants enrolled in this study will be asked to use their existing ventilator for up to 1 hour to collect pressure and flow data for comparison purposes against the Helix ventilator. Participants will then be set up on the Helix Ventilatory System using the same mode of therapy as their current ventilator. Participants may receive mechanical ventilation using any patient circuit currently being designed for the Helix Ventilator (Passive, Active with Positive Airway Pressure (PAP), Active with Flow, or dual limb). Patients currently using non-invasive ventilation may be asked to use a mouth piece in lieu of a mask interface. While using the study device, therapy setting may be altered by the physician or his/her surrogate while maintaining the ventilator needs of the patient. For e.g.,a patient currently prescribed an synchronized intermittent mechanical ventilation (SIMV) mode may temporarily be switched to a pressure control mode to assess patient synchrony and ventilator performance. Once the participant is set-up, he/she will be asked to use the ventilator for up to 4 hours. During this time, Philips Respironics engineers will be collecting data through several mechanisms: 1) Helix SanDisc (SD) Card, 2) Non-invasive Cardiac Output (NICO) Monitoring System, and / or 3) External data collection device (ex. laptop). The study staff may ask the participant's opinions on the comfort of the therapy delivery. There will be no invasive monitoring as part of this study. The engineering evaluations will take place at the Boston Children's Health Physician offices. The study investigators, respiratory therapist, and/or other qualified clinical staff, will be supervising and present for all study visits. Philips Respironics engineers will be present for observational purposes only. All study staff working on this trial will be trained to the protocol and device prior to beginning work. Participants may be asked to participate in this data collection study up to six (6) times. Study data collected for this study will be collected on paper or electronic source records. These records will include information regarding inclusion/exclusion, performed study procedures and questions regarding device use. Only those staff that have been delegated by the Principal Investigator will be able to enter or make changes to the data in the Case Report Forms.

Interventions

DEVICEHelix Ventilator

The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.

Sponsors

Philips Respironics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

This trial is an engineering study is to verify the overall performance and controls of the Helix Ventilator as compared to the participant's current therapy device.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Participants who are currently using mechanical ventilation (\> 1 month at time of study participation) as part of medical care and have demonstrated a clinically acceptable response to this therapy and meet the following inclusion criteria: 1. Weight \> 5Kg; 2. Any medical condition requiring mechanical ventilation through nasal/facial mask, mouthpiece or tracheostomy 3. Any medical condition requiring mechanical ventilation for \> 1 month

Exclusion criteria

1. Participants intubated with an endotracheal tube 2. Clinically unstable, i.e., 1. Acute Respiratory Failure 2. Participants with refractory hypotension (defined as systolic blood pressure less than 90 mm Hg despite inotropic agents) 3. Uncontrolled cardiac ischemia or arrhythmias d. Any participant determined as inappropriate for the study by the Principal Investigator 3. Patients suffering from metastatic or terminal cancer 4. Currently employed by a manufacturer of respiratory products or family member employed by a manufacturer of respiratory products 5. Patient of surrogate is unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Proximal Pressure From Trilogy Evo Ventilator and Current Device1 dayProximal pressure from the participant's Trilogy Evo ventilator and current device
Proximal Flow From Trilogy Evo and Patient's Current Device1 dayProximal flow from Trilogy Evo and patient's current device

Secondary

MeasureTime frameDescription
Subjective Ease-of-Operation Rating Regarding Trilogy Device1 daySubjective Ease-of-Operation rating (1-Very Easy to 5-Very Hard) regarding Trilogy device

Countries

United States

Participant flow

Participants by arm

ArmCount
Evaluable Population
This population of non-invasive patients completed the engineering evaluation and utilized settings that allowed proper comparison between Trilogy and their current ventilator.
13
Non-Evaluable Population
This population included N=2 invasive-ventilator patients, as well as N=1 who did not complete the engineering evaluation, and N=4 who were only included for the purposes of testing the updated leak algorithm.
7
Total20

Baseline characteristics

CharacteristicEvaluable PopulationTotalNon-Evaluable Population
Age, Continuous11.3 years
STANDARD_DEVIATION 10.2
13.1 years
STANDARD_DEVIATION 9.7
16.3 years
STANDARD_DEVIATION 8.5
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants7 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants13 Participants7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants2 Participants2 Participants
Race (NIH/OMB)
Asian
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Black or African American
1 Participants1 Participants0 Participants
Race (NIH/OMB)
More than one race
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
11 Participants15 Participants4 Participants
Region of Enrollment
United States
13 participants20 participants7 participants
Sex: Female, Male
Female
6 Participants11 Participants5 Participants
Sex: Female, Male
Male
7 Participants9 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
0 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Proximal Flow From Trilogy Evo and Patient's Current Device

Proximal flow from Trilogy Evo and patient's current device

Time frame: 1 day

Population: This population of non-invasive patients completed the engineering evaluation and utilized settings that allowed proper comparison between Trilogy and their current ventilator. It excludes N=2 invasive-ventilator patients, as well as N=1 who did not complete the engineering evaluation, and N=4 who were only included for the purposes of testing the updated leak algorithm.

ArmMeasureValue (MEAN)Dispersion
Evaluable Population: Trilogy EvoProximal Flow From Trilogy Evo and Patient's Current Device4.2 Liters / minuteStandard Deviation 4.5
Evaluable Population: Current DeviceProximal Flow From Trilogy Evo and Patient's Current Device4.9 Liters / minuteStandard Deviation 5.7
Primary

Proximal Pressure From Trilogy Evo Ventilator and Current Device

Proximal pressure from the participant's Trilogy Evo ventilator and current device

Time frame: 1 day

Population: This population of non-invasive patients completed the engineering evaluation and utilized settings that allowed proper comparison between Trilogy and their current ventilator. It excludes N=2 invasive-ventilator patients, as well as N=1 who did not complete the engineering evaluation, and N=4 who were only included for the purposes of testing the updated leak algorithm.

ArmMeasureValue (MEAN)Dispersion
Evaluable Population: Trilogy EvoProximal Pressure From Trilogy Evo Ventilator and Current Device8.3 cm H2OStandard Deviation 1.6
Evaluable Population: Current DeviceProximal Pressure From Trilogy Evo Ventilator and Current Device8.2 cm H2OStandard Deviation 3
Secondary

Subjective Ease-of-Operation Rating Regarding Trilogy Device

Subjective Ease-of-Operation rating (1-Very Easy to 5-Very Hard) regarding Trilogy device

Time frame: 1 day

Population: This population of non-invasive patients completed the engineering evaluation and utilized settings that allowed proper comparison between Trilogy and their current ventilator. It excludes N=2 invasive-ventilator patients, as well as N=1 who did not complete the engineering evaluation, and N=4 who were only included for the purposes of testing the updated leak algorithm. Data not available from N=1 participant.

ArmMeasureValue (MEAN)Dispersion
Evaluable Population: Trilogy EvoSubjective Ease-of-Operation Rating Regarding Trilogy Device1.9 scores on a scaleStandard Deviation 0.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026